Ayr Wellness Past Earnings Performance
Past criteria checks 0/6
Ayr Wellness's earnings have been declining at an average annual rate of -26.3%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 30.2% per year.
Key information
-26.3%
Earnings growth rate
34.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 30.2% |
| Return on equity | -43.4% |
| Net Margin | -48.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Ayr Wellness Inc.'s (CSE:AYR.A) 29% Share Price Surge Not Quite Adding Up
Nov 03
Ayr Wellness (CSE:AYR.A) Has Debt But No Earnings; Should You Worry?
Oct 23Ayr Wellness Inc. (CSE:AYR.A) Not Doing Enough For Some Investors As Its Shares Slump 28%
Aug 28Does Ayr Wellness (CSE:AYR.A) Have A Healthy Balance Sheet?
Jul 17Ayr Wellness Inc.'s (CSE:AYR.A) Shares Not Telling The Full Story
May 24Is Ayr Wellness Inc. (CSE:AYR.A) Worth CA$2.1 Based On Its Intrinsic Value?
Dec 22Is Ayr Wellness (CSE:AYR.A) Using Debt Sensibly?
Oct 06Ayr Wellness Inc.'s (CSE:AYR.A) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Sep 01Ayr Wellness Inc. (CSE:AYR.A) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Sep 01Is There An Opportunity With Ayr Wellness Inc.'s (CSE:AYR.A) 33% Undervaluation?
Jul 11What You Need To Know About The Ayr Wellness Inc. (CSE:AYR.A) Analyst Downgrade Today
Aug 19Does Ayr Wellness (CSE:AYR.A) Have A Healthy Balance Sheet?
Jul 23Revenue & Expenses Breakdown
How Ayr Wellness makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 465 | -223 | 166 | 0 |
| 30 Jun 24 | 465 | -191 | 160 | 0 |
| 31 Mar 24 | 464 | -183 | 165 | 0 |
| 31 Dec 23 | 464 | -86 | 178 | 0 |
| 30 Sep 23 | 463 | -190 | 203 | 0 |
| 30 Jun 23 | 457 | -206 | 215 | 0 |
| 31 Mar 23 | 440 | -211 | 216 | 0 |
| 31 Dec 22 | 421 | -207 | 213 | 0 |
| 30 Sep 22 | 419 | -51 | 195 | 0 |
| 30 Jun 22 | 406 | -21 | 182 | 0 |
| 31 Mar 22 | 399 | -6 | 169 | 0 |
| 31 Dec 21 | 358 | -17 | 144 | 0 |
| 30 Sep 21 | 294 | -42 | 113 | 0 |
| 30 Jun 21 | 243 | -38 | 90 | 0 |
| 31 Mar 21 | 180 | -27 | 75 | 0 |
| 31 Dec 20 | 155 | -25 | 72 | 0 |
| 30 Sep 20 | 140 | -41 | 77 | 0 |
| 30 Jun 20 | 126 | -16 | 82 | 0 |
| 31 Mar 20 | 109 | -42 | 71 | 0 |
| 31 Dec 19 | 75 | -164 | 49 | 0 |
| 30 Sep 19 | 43 | -191 | 31 | 0 |
| 30 Jun 19 | 11 | -242 | 11 | 0 |
| 31 Mar 19 | 0 | -209 | 3 | 0 |
Quality Earnings: AYR.A is currently unprofitable.
Growing Profit Margin: AYR.A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AYR.A is unprofitable, and losses have increased over the past 5 years at a rate of 26.3% per year.
Accelerating Growth: Unable to compare AYR.A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AYR.A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: AYR.A has a negative Return on Equity (-43.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 12:18 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ayr Wellness Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Kenric Tyghe | ATB Capital Markets |
| Russell Stanley | Beacon Securities Limited |